Fresenius takes full ownership of mAbxience in biosimilars push
What's the deal? FreseniusDealroom has a profile for this one. Try Dealroom → has acquired the remaining 45% of biosimilars maker mAbxienceDealroom has a profile for this one. Try Dealroom → from Insud PharmaDealroom has a profile for this one. Try Dealroom →, giving the German healthcare group full ownership of the Madrid-based company. The German healthcare group bought a 55% majority stake in August 2022 and has consolidated the business since. Terms were not disclosed.
What's the endgame? mAbxience now sits wholly within Fresenius Kabi's Biopharma unitDealroom has a profile for this one. Try Dealroom →, which spans development, manufacturing, and commercialisation. Full ownership gives Fresenius control over cost, capacity, and launch timing — plus the full economic benefit.
Why now? A large wave of biologic drugs is losing patent exclusivity, opening the market to lower-cost biosimilar copies. "The market opportunity was promising but still evolving" when Fresenius first invested four years ago, said chief executive officer Michael Sen. "Since then, the market has developed strongly, mAbxience has delivered, and Fresenius now has the financial strength to take this next step."
What changes for customers? Little, for now. mAbxience said it will keep supporting existing customers and partners and remains committed to reliable supply of its biosimilars.
The signal: The deal reflects a broader push by large drugmakers to build vertically integrated biosimilars platforms ahead of a flood of expiring biologic patents. For Fresenius, moving from a risk-managed majority stake to full control signals confidence that the biosimilars opportunity has matured enough to own outright.
Read more: centralcharts.com
Image credit: Generated with Gemini
